Gregory Papa, DO
Family Medicine · New Castle, DENPI 1730242397
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.6%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 49 manufacturers reported payments, led by AbbVie at 48.6% of the total. Reporting peaked in 2021 at $20,296 and has fallen 81.9% since, to $3,664 in 2025. Among family medicine clinicians in DE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,610 payments — averaging $41.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$33K
- Biohaven Pharmaceuticals, Inc.$10K
- Novo Nordisk$4K
- AstraZeneca$3K
- Biohaven Pharmaceutical Holding Company Ltd.$3K
- GSK$2K
- plus $13K from 43 others
What the payments were for
- Consulting fees$1,2002%
- Speaking & faculty fees$37,92557%
- Travel & lodging$6421%
- Food & beverage$26,93240%
- Education$2700%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$66,969 in reported general payments places this provider in the 95th percentile of 352 family medicine providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 143 | $159,959 |
| FarxigaDapagliflozin Propanediol | 108 | $83,955 |
| JardianceEmpagliflozin | 52 | $71,880 |
| EliquisApixaban | 64 | $57,249 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 77 | $55,831 |
| TrulicityDulaglutide | 26 | $42,665 |
| MounjaroTirzepatide | 28 | $39,782 |
| XareltoRivaroxaban | 40 | $26,775 |
| MyrbetriqMirabegron | 41 | $25,659 |
| RybelsusSemaglutide | 17 | $25,410 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 39 | $20,893 |
| JanumetSitagliptin Phos/Metformin Hcl | 18 | $18,393 |
| Hysingla ErHydrocodone Bitartrate | 13 | $16,982 |
| Tresiba Flextouch U-100Insulin Degludec | 21 | $15,778 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 95 | $14,363 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $3,759 | $185,369160 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat, Spiriva Respimat | $616 | $84,73078 claims |
| AstraZenecaFarxiga | $2,909 | $83,955108 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $543 | $82,44654 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $1,849 | $76,725116 claims |
| PfizerEliquis | $1,747 | $57,24964 claims |
| Johnson & JohnsonXarelto | $876 | $26,77540 claims |
| Astellas Pharma US IncMyrbetriq | $773 | $25,65941 claims |
| MerckJanumet | $243 | $18,39318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 352 family medicine providers in Delaware.
Other family medicine in New Castle
- Khaja YezdaniNew Castle$7K
- Sarah MullinsWilmington$36K
- Ashley PanichelliWilmington$27K
- Michelle PapaNewark$23K
- Maryann ConnorWilmington$21K
- Jill MackeyWilmington$20K
- Wayne TuckerBear$20K
- Ian MyersNewark$17K
- Glenn HamiltonWilmington$17K
- Dustin DavisGeorgetown$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.